庆大霉素外用治疗无义突变所致遗传性皮肤病的探索性试验

注册号:

Registration number:

ChiCTR1800014771 

最近更新日期:

Date of Last Refreshed on:

2018-02-04 13:05:12 

注册时间:

Date of Registration:

2018-02-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

庆大霉素外用治疗无义突变所致遗传性皮肤病的探索性试验

Public title:

The Exploratory Research of Gentamicin Topical Treatment of Genodermatosis Caused by Nonsense Mutations

注册题目简写:

English Acronym:

研究课题的正式科学名称:

庆大霉素外用治疗无义突变所致遗传性皮肤病的探索性试验

Scientific title:

The Exploratory Research of Gentamicin Topical Treatment of Genodermatosis Caused by Nonsense Mutations

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李越 

研究负责人:

姚志荣 

Applicant:

Yue Li 

Study leader:

Zhirong Yao 

申请注册联系人电话:

Applicant telephone:

+86 15221208796

研究负责人电话:

Study leader's
telephone:

+86 021-25076428

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dath1994@sina.com

研究负责人电子邮件:

Study leader's E-mail:

zryaoxh@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市杨浦区控江路1665号

研究负责人通讯地址:

上海市杨浦区控江路1665号

Applicant address:

1665 Kongjiang Road, Yangpu District, Shanghai, China

Study leader's address:

1665 Kongjiang Road, Yangpu District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属新华医院

Applicant's institution:

Xinhua Hospital Affiliated to Shanghai Jiaotong University school of Medicine

研究负责人所在单位:

上海交通大学医学院附属新华医院

Affiliation of the Leader:

Xinhua Hospital Affiliated to Shanghai Jiaotong University school of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XHEC-C-2017-1092

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属新华医院伦理委员会

Name of the ethic committee:

Ethics Committee Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2018-01-17 00:00:00

伦理委员会联系人:

李劲松

Contact Name of the ethic committee:

Jinsong Li

伦理委员会联系地址:

上海市杨浦区控江路1665号

Contact Address of the ethic committee:

1665 Kongjiang Road, Yangpu District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属新华医院

Primary sponsor:

Zhirong Yao

研究实施负责(组长)单位地址:

上海市杨浦区控江路1665号

Primary sponsor's address:

1665 Kongjiang Road, Yangpu District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

杨浦区

Country:

China

Province:

Shanghai

City:

单位(医院):

新华医院

具体地址:

上海市杨浦区控江路1665号

Institution
hospital:

Xinhua Hospital

Address:

1665 Kongjiang Road, Yangpu District, Shanghai, China

经费或物资来源:

上海市教委

Source(s) of funding:

Shanghai Municipal Education Commission

研究疾病:

无义突变导致的遗传性皮肤病  

Target disease:

Genodermatosis Caused by Nonsense Mutations

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

评价庆大霉素外用治疗无义突变所致遗传性皮肤病,如鱼鳞病,遗传性大疱性表皮松解症,着色性干皮病,掌跖角化病等遗传性皮肤病的有效性、安全性。  

Objectives of Study:

Evaluating the effectiveness and safety of topical gentamicin treatment of Genodermatosis caused by nonsense mutations, such as ichthyosis,Epidermolysis bullosa dystrophica, dermatological dermatosis, palmoplantar keratoses and other hereditary dermatoses.

药物成份或治疗方案详述:

治疗方案:每例患者进行每日一次庆大霉素乳膏于患处(双侧对比,一侧用药,一侧安慰剂)涂抹(Day 1- Day 30),前后对照。 1) 名称:庆大霉素乳膏。 2) 来源:新华医院药剂科。 3) 成分:硫酸庆大霉素,单硬脂酸甘油酯,硬脂酸,轻质液状石蜡,十二烷基硫酸钠,三乙醇胺,甘油,月桂氮卓酮,羟苯乙酯,蒸馏水。 4) 规格:0.03%,0.1%,0.3% 5) 用法:外用 6) 疗程:每日一次,维持30天。 

Description for medicine or protocol of treatment in detail:

Treatment regimen: Each patient was given gentamicin ointment once daily (Day 1 to Day 30), with before and after contrast (bilateral contrast, one-side treatment, one side placebo). 1) Name: Gentamycin ointment. 2) Source: Xinhua Hospital Pharmacy. 3) Ingredients: gentamicin sulfate, glyceryl monostearate, stearic acid, light liquid paraffin, sodium lauryl sulfate, triethanolamine, glycerol, laurel, phenethyl, distilled water. 4) Specifications: 0.03%, 0.1%, 0.3% 5) Usage: external use 6) treatment: once daily for 30 days. 

纳入标准:

Inclusion criteria

排除标准:

1) 对拟使用药物中的任何成分,有过敏史的患者。
2)对青霉素、氨基糖苷类过敏的患者;
3)有支气管哮喘病史的患者。
4)有急性感染体征的患者。
5)有HIV,HBV,HCV等慢性感染患者。
6)有第8对脑神经损害,重症肌无力或帕金森病史。
7)哺乳期妇女,孕妇或在治疗期间有潜在怀孕可能,且拒绝避孕的患者。
8)心电图、胸片、超声、肝、肾功能异常,且存在临床意义;
9)基因筛查发现耳聋基因或存在听力受损;
10)根据研究者判断,受试者不可信或依从性差者。

Exclusion criteria:

1) Patients who have a history of allergies to any of the ingredients to be used;
2) penicillin, aminoglycoside allergic patients;
3) Patients with a history of bronchial asthma;
4) Patients with signs of acute infection;
5) HIV, HBV, HCV and other chronic infections in patients;
6) There is a eighth cranial nerve damage, myasthenia gravis or Parkinson's disease history;
7) Lactating women, pregnant women, or those who have potential pregnancies during treatment and who refuse contraception;
8) ECG, chest radiograph, ultrasound, liver and kidney dysfunction with clinical significance;
9) gene screening found deafness genes or the presence of hearing impairment;
10) At the discretion of the investigator, the subjects were either untrustworthy or poorly compliant.

研究实施时间:

Study execute time:

From 2018-01-22 00:00:00 To 2019-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-01-23 00:00:00 To 2018-06-01 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

9

Group:

Case series

Sample size:

干预措施:

庆大霉素外用治疗

干预措施代码:

Intervention:

Topical gentamicin treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

杨浦区 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属新华医院 

单位级别:

三级甲等 

Institution
hospital:

Xinhua Hospital Affiliated to Shanghai jiaotong university school of medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

组织病理

指标类型:

主要指标

Outcome:

histopathology

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电镜

指标类型:

主要指标

Outcome:

electron microscope

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮肤组织蛋白表达

指标类型:

主要指标

Outcome:

Expression of protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床表现

指标类型:

次要指标

Outcome:

clinical manifestation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

听力

指标类型:

副作用指标

Outcome:

audition

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

副作用指标

Outcome:

renal function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

皮肤组织

组织:

皮肤

Sample Name:

skin tissue

Tissue:

skin

人体标本去向

使用后保存  

说明

病理切片

Fate of sample:

Preservation after use  

Note:

pathological section

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Viedoc临床试验系统(https://v4jp.viedoc.net/Account/LogOn?ReturnUrl=%2fHome%2fIndex)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Viedoc Clinical Trial System(https://v4jp.viedoc.net/Account/LogOn?ReturnUrl=%2fHome%2fIndex)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表采集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

we collecting data by CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2018-02-04 13:05:12